The rise of gonococcal resistance (particularly to extended-spectrum cephalosporins) poses an increasing problem for testing. Wind et al 1 looks at the use of ESure swabs for Gonorrhoea testing. A NAAT to diagnose gonorrhoea combined with a way to defer culture of positive samples would be useful but needs a specialised collection medium to enable N.gonorrhoea to survive and maintain diagnostic sensitivity. The ESwab system (Copan, Italy) is known to prolong survival of other bacterial species.
Swabs for NAAT and culture
The rise of gonococcal resistance (particularly to extended-spectrum cephalosporins) poses an increasing problem for testing. Wind et al 1 looks at the use of ESure swabs for Gonorrhoea testing. A NAAT to diagnose gonorrhoea combined with a way to defer culture of positive samples would be useful but needs a specialised collection medium to enable N.gonorrhoea to survive and maintain diagnostic sensitivity. The ESwab system (Copan, Italy) is known to prolong survival of other bacterial species.
Wind et al hypothesised that ESwabs could be used for deferred gonorrhoea culture and aimed to determine: 1)if culture was possible 3 days after storing samples and 2)
would ESwab NAAT testing result in any loss of diagnostic sensitivity. 2452 samples were taken from 1893 high risk patients (symptomatic, MSM or STI contacts) attending a sexual health clinic. In men a direct GC culture, and first void urine or rectal NAAT (in MSM) were taken. In women cervical or rectal swabs NAATs were sent. Single ESwab samples were taken from each anatomical site for each patient except for urine samples where floculated ESwabs were dipped into first pass urine within 30 minutes of collection. NAAT samples were taken first follwed by ESure for the first half of the study and then reversed. Direct urethral sampling of either sample was against clinic policy at the study site. The ESwab NAAT was less sensitive (83%; 95% CI 75-90%) than the Aptima combo NAAT for GC and ESwabs were more sensitive for those patients with symptoms vs asymptomatic (p=0.001). For CT ESwab NAAT sensitivity was 87% (95% CI 82-90%) with 6 positive on ESwab but infections occurred after 6 months of breastfeeding and 2 occurred because breastfeeding had not completely stopped. They found that the two regimen are equally effective and have similar rates of side effects but that adherance plays a role in transmission risk and there is a benefit to continuing infant PEP for the duration of breastfeeding.
Investment in infectious diseases research
Head and colleagues looked, in this interesting paper, at the funding awarded to Uk insututions for research into HIV, TB and malaria from 1997-2010. They assessed investment from 585 awarding bodies and analysed publication and citation rates for these 3 areas. An 'investment by publication' metric was generated, and an 'investment by citation' metric was developed as a measure of the 'usefulness' of research. 17,271 publications were included (9322 for HIV, 4451 for malaria and 3498 for TB). TB research was most productive for investors; cost per publication £50,691 (HIV £61,971 and malaria £94,483). £1,797 was spent per citation for TB (lowest). Overall pre-clinical science received the most funding, public health came out as the cost productive for HIV and TB, but phase I-III trials were the most productive for malaria. The authors comment that they had only looked at this snapshot of publicly funded research and that further work is ongoing. The actual figures involved were of interest and highlights the respomsibility we have to use funds widely and disseminate findings.
